Ocugen Inc (OCGN) - Market Cap to Net Income Ratio

Symbol and logo of brand Ocugen Inc (OCGN)

Ocugen, Inc. (OCGN) develops advanced biologics, optimizing component logistics through global partners to drive profit growth. Strict FDA regulations and patent protection for ophthalmological platforms ensure a high barrier to entry. The market dynamics reflected in the price action on GURU.Markets with the -4.30 indicator confirm the potential of the company, whose revenue relies on government procurement of therapies for the treatment of infections and retinal degeneration.

OCGN Ocugen Inc: Price to Earnings Ratio in the range 07/04/2022 - 11/16/2026

Comprehensive metric breakdowns and analytics for ocugen.com (OCGN)

- price and consensus price forecast:
Comprehensive company analysis:Ocugen OCGN
Flagship merchandise of Ocugen, Inc.

Investors are seeking resilient assets, utilizing multiples to assess the market value of a business relative to its earnings. The P/E ratio measures the relationship between the current share price and earnings per share, determining the payback period for the investment. For Ocugen, Inc. (OCGN), whose gene therapies are currently in the trial stage, this calculation reflects market expectations for future breakthroughs in treating blindness. By analyzing the fundamental P/E of Ocugen, Inc. (OCGN), one can evaluate the extent of the premium paid for the potential of its long-term lifecycle.

Key competitors

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Beam Therapeutics Corp - Company Value to Net Income|Price to Earnings Ratio SRPT|twistbioscience.com (TWST) - Business Payback Period|P/E Multiple TXG|NTLA (Intellia) - Company Value to Net Income|Price to Earnings Ratio Stoke STOK|BioLife (BLFS) - Market Cap to Earnings|wavelifesciences.com - P/E Multiple|Market Cap to Net Income MAZE|SION: P/E Multiple|PRME - Business Payback Period|Price to Earnings Ratio TSHA|QURE - Market Cap to Net Income Ratio|P/E Multiple MGTX|Business Payback Period regenxbio.com|P/E Multiple SLDB (Solid Biosciences Inc)|Pacific Biosciences of California, Inc. (PACB) - Market Cap to Earnings|BNTC - Price to Earnings Ratio|Design Pharma - Market Price to Net Income Ratio|RCKT (Rocket Pharmaceuticals Inc) - Price to Earnings Ratio|4D Molecular Therapeutics (FDMT) - P/E Multiple|Price to Earnings Ratio Lexeo Therapeutics, Inc.|Market Cap to Earnings Korro Bio, Inc. KRRO|P/E Multiple EDIT|Business Payback Period Silence Therapeutics Corp|Price to Earnings Ratio proqr.com PRQR|CDXS - Price to Earnings Ratio|SGMO - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio